Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

References

• Abrahamson DR, Powers A, Rodewald R. (1979). Intestinal absorption of immune complexes by neonatal rats: a route of antigen transfer from mother to young. Science, 206, 567–9
   PubMed Web of Science ®Google Scholar
• Adamski FM, King AT, Demmer J. (2000). Expression of the Fc receptor in the mammary gland during lactation in the marsupial Trichosurus vulpecula (brushtail possum). Mol Immunol, 37, 435–44
   PubMed Web of Science ®Google Scholar
• Aggarwal S. (2011). What’s fueling the biotech engine – 2010 to 2011. Nature Biotechnol, 29, 1083–9
   PubMed Web of Science ®Google Scholar
• Ahouse JJ, Hagerman CL, Mittal P, et al. (1993). Mouse MHC class I-like Fc receptor encoded outside the MHC. J Immunol, 151, 6076–88
   PubMed Web of Science ®Google Scholar
• Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. (2007). Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol, 179, 4580–8
   PubMed Web of Science ®Google Scholar
• Amevive®. (2011). Prescribing information. Available from: http://www.astellas.us/docs/amevive.pdf [last accessed 24 Apr 2012]
   Google Scholar
• Anderson CL, Chaudhury C, Kim J, et al. (2006). Perspective – FcRn transports albumin: relevance to immunology and medicine. Trends Immunol, 27, 343–8
   PubMed Web of Science ®Google Scholar
• Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. (2011). Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature, 475, 110–3
   PubMed Web of Science ®Google Scholar
• Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. (2008). Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A, 105, 19571–8
   PubMed Web of Science ®Google Scholar
• Arcalyst. (2010). Prescribing information. Available from: http://www.regeneron.com//ArcalystPI-US-Summary-EMEA/Arcalyst PI_June_2010r3-1.pdf [last accessed 24 Apr 2012]
   Google Scholar
• Arnold JN, Wormald MR, Sim RB, et al. (2007). The impact of glycosylation on the biological function and structure of human immunoglobulins. Ann Rev Immunol, 25, 21–50
   PubMed Web of Science ®Google Scholar
• Bai Y, Ye L, Tesar DB, et al. (2011). Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci U S A, 108, 18406–11
   PubMed Web of Science ®Google Scholar
• Baker K, Qiao SW, Kuo T, et al. (2009). Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol, 31, 223–36
   PubMed Web of Science ®Google Scholar
• Baker K, Qiao SW, Kuo TT, et al. (2011). Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A, 108, 9927–32
   PubMed Web of Science ®Google Scholar
• Baker K, Rath T, Lencer WI, et al. (2012). Cross-presentation of IgG-containing immune complexes. Cell Mol Life Sci, 70, 1319–34
   PubMed Web of Science ®Google Scholar
• Beck A. (2011). Biosimilar, biobetter and next generation therapeutic antibodies. MAbs, 3, 107–10
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia, N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol, 10, 345–52
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Corvaia N. (2008). Therapeutic antibodies and derivatives: from the bench to the clinic. Curr Pharm Biotechnol, 9, 421–2
   PubMed Web of Science ®Google Scholar
• Ben Suleiman Y, Yoshida M, Nishiumi S, et al. (2012). Neonatal Fc receptor for IgG (FcRn) expressed in the gastric epithelium regulates bacterial infection in mice. Mucosal Immunol, 5, 87–98
   PubMed Web of Science ®Google Scholar
• Bitonti AJ, Dumont JA. (2006). Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev, 58, 1106–18
   PubMed Web of Science ®Google Scholar
• Bitonti AJ, Dumont JA, Low SC, et al. (2004). Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A, 101, 9763–8
   PubMed Web of Science ®Google Scholar
• Borel Y. (1980). Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression. Immunol Rev, 50, 71–104
   PubMed Web of Science ®Google Scholar
• Borys MC, Dalal NG, Abu-Absi NR, et al. (2010). Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol Bioeng, 105, 1048–57
   Google Scholar
• Bracewell C, Isaacs JD, Emery P, Ng WF. (2009). Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther, 9, 909–19
   PubMed Web of Science ®Google Scholar
• Brambell FW. (1963). Resemblances between passive anaphylactic sensitization and transmission of passive immunity. Nature, 199, 1164–6
   PubMed Web of Science ®Google Scholar
• Brambell FW, Hemmings WA, Morris IG. (1964). A theoretical model of gamma-globulin catabolism. Nature, 203, 1352–4
   PubMed Web of Science ®Google Scholar
• Burge DJ, Bookbinder SA, Kivitz AJ, et al. (2008). Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. Clin Ther, 30, 1806–16
   PubMed Web of Science ®Google Scholar
• Burmeister WP, Gastinel LN, Simister NE, et al. (1994a). Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature, 372, 336–43
   PubMed Web of Science ®Google Scholar
• Burmeister WP, Huber AH, Bjorkman PJ. (1994b). Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature, 372, 379–83
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, et al. (2009). Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood, 113, 2161–71
   PubMed Web of Science ®Google Scholar
• Byrn RA, Mordenti J, Lucas C, et al. (1990). Biological properties of a CD4 immunoadhesin. Nature, 344, 667–70
   PubMed Web of Science ®Google Scholar
• Capon DJ, Chamow SM, Mordenti J, et al. (1989). Designing CD4 immunoadhesins for AIDS therapy. Nature, 337, 525–31
   PubMed Web of Science ®Google Scholar
• Chamian F, Lowes MA, Lin SL, et al. (2005). Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A, 102, 2075–80
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. (2010). Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol, 10, 301–16
   PubMed Web of Science ®Google Scholar
• Chaudhury C, Mehnaz S, Robinson JM, et al. (2003). The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med, 197, 315–22
   PubMed Web of Science ®Google Scholar
• Chu QS. (2009). Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther, 9, 263–71
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Berlin J, Chan E. (2013). Aflibercept. Clin Cancer Res, 19, 1920–5
   PubMed Web of Science ®Google Scholar
• Coleman RL, Duska LR, Ramirez PT, et al. (2011). Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol, 12, 1109–17
   PubMed Web of Science ®Google Scholar
• Collen D, Bernaerts R, Declerck P, et al. (1996a). Recombinant staphylokinase variants with altered immunoreactivity. I: construction and characterization. Circulation, 94, 197–206
   PubMed Web of Science ®Google Scholar
• Collen D, Moreau H, Stockx L, Vanderschueren S. (1996b). Recombinant staphylokinase variants with altered immunoreactivity. II: thrombolytic properties and antibody induction. Circulation, 94, 207–16
   PubMed Web of Science ®Google Scholar
• Cwirla SE, Balasubramanian P, Duffin DJ, et al. (1997). Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science, 276, 1696–9
   PubMed Web of Science ®Google Scholar
• Dall’acqua WF, Kiener PA, Wu H. (2006). Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem, 281, 23514–24
   PubMed Web of Science ®Google Scholar
• Dall’acqua WF, Woods RM, Ward ES, et al. (2002). Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol, 169, 5171–80
   PubMed Web of Science ®Google Scholar
• Dall’era M, Chakravarty E, Wallace D, et al. (2007). Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum, 56, 4142–50
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, et al. (2007). Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem, 282, 1709–17
   PubMed Web of Science ®Google Scholar
• De Groot AS, Martin W. (2009). Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol, 131, 189–201
   PubMed Web of Science ®Google Scholar
• De Groot AS, Moise L, Mcmurry JA, et al. (2008). Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood, 112, 3303–11
   PubMed Web of Science ®Google Scholar
• De Groot AS, Scott DW. (2007). Immunogenicity of protein therapeutics. Trends Immunol, 28, 482–90
   PubMed Web of Science ®Google Scholar
• De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. (2009). Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis, 68, 531–5
   PubMed Web of Science ®Google Scholar
• Deisenhofer J. (1981). Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry, 20, 2361–70
   PubMed Web of Science ®Google Scholar
• Deng R, Loyet KM, Lien S, et al. (2010). Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos, 38, 600–5
   PubMed Web of Science ®Google Scholar
• Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, et al. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Br J Cancer, 107, 604–11
   PubMed Web of Science ®Google Scholar
• Dickinson BL, Badizadegan K, Wu Z, et al. (1999). Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest, 104, 903–11
   PubMed Web of Science ®Google Scholar
• Dore RK, Mathews S, Schechtman J, et al. (2007). The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol, 25, 40–6
   PubMed Web of Science ®Google Scholar
• Doronina SO, Mendelsohn BA, Bovee TD, et al. (2006). Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem, 17, 114–24
   PubMed Web of Science ®Google Scholar
• Dumont JA, Bitonti AJ, Clark D, et al. (2005). Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med, 18, 294–303
   PubMedGoogle Scholar
• Dumont JA, Liu T, Low SC, et al. (2012). Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 119, 3024–30
   PubMed Web of Science ®Google Scholar
• Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006). Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs, 20, 151–60
   PubMed Web of Science ®Google Scholar
• Dumont JA, Low SC, Peters RT, Bitonti AJ. (2009). Monomeric Fc fusion molecules, in: therapeutic monoclonal antibodies: from bench to clinic. Hoboken, NJ: John Wiley & Sons Inc
   Google Scholar
• Economides AN, Carpenter LR, Rudge JS, et al. (2003). Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med, 9, 47–52
   PubMed Web of Science ®Google Scholar
• Enbrel®. (2011). Prescribing Information. Available from: http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf [last accessed 24 Apr 2012]
   Google Scholar
• Ephrem A, Chamat S, Miquel C, et al. (2008). Expansion of CD4 + CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood, 111, 715–22
   PubMed Web of Science ®Google Scholar
• Eylea. (2011). Prescribing information. Available from: http://www.regeneron.com/Eylea/eylea-fpi.pdf [last accessed 24 Apr 2012]
   Google Scholar
• Firan M, Bawdon R, Radu C, et al. (2001). The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol, 13, 993–1002
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Cohen SB, Stanley B, et al. (2010). Evidence of peripheral B cell depletion in subjects with controlled lupus erythematosus (SLE) following subcutaneous administration of SBI-087 (Abstract). Arthritis Rheum, 62, 1154
   Google Scholar
• Freyer G, Isambert N, You B, et al. (2012). Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. Br J Cancer, 107, 598–603
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kinnman N, De la Bourdonnaye G, et al. (2011). Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum, 63, 1793–803
   PubMed Web of Science ®Google Scholar
• Ghaderi D, Taylor RE, Padler-Karavani V, et al. (2010). Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nature Biotechnol, 28, 863–7
   PubMed Web of Science ®Google Scholar
• Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. (2012). Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev, 28, 147–75
   PubMed Web of Science ®Google Scholar
• Ghetie V, Hubbard JG, Kim JK, et al. (1996). Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol, 26, 690–6
   PubMed Web of Science ®Google Scholar
• Ghose S, Hubbard B, Cramer SM. (2006). Evaluation and comparison of alternatives to protein A chromatography mimetic and hydrophobic charge induction chromatographic stationary phases. J Chromatogr A, 1122, 144–52
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. (2012). Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther, 14, R33
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG. (2003). Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol, 2, 624–8
   PubMedGoogle Scholar
• Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL. (2006). Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol, 43, 1462–73
   PubMed Web of Science ®Google Scholar
• Haggerty HG, Abbott MA, Reilly TP, et al. (2007). Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol, 34, 2365–73
   PubMed Web of Science ®Google Scholar
• Hayden-Ledbetter MS, Cerveny CG, Espling E, et al. (2009). CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res, 15, 2739–46
   PubMed Web of Science ®Google Scholar
• He Y, Bjorkman PJ. (2011). Structure of FcRY, an avian immunoglobulin receptor related to mammalian mannose receptors, and its complex with IgY. Proc Natl Acad Sci U S A, 108, 12431–6
   PubMed Web of Science ®Google Scholar
• Hinton PR, Johlfs MG, Xiong JM, et al. (2004). Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem, 279, 6213–6
   PubMed Web of Science ®Google Scholar
• Hinton PR, Xiong JM, Johlfs MG, et al. (2006). An engineered human IgG1 antibody with longer serum half-life. J Immunol, 176, 346–56
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. (2008). Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum, 58, 2443–52
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A, 99, 11393–8
   PubMed Web of Science ®Google Scholar
• Huang C. (2009). Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol, 20, 692–9
   PubMed Web of Science ®Google Scholar
• Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ. (1993). Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol, 230, 1077–83
   PubMed Web of Science ®Google Scholar
• Huber R, Deisenhofer J, Colman PM, et al. (1976). Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature, 264, 415–20
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. (2005). Immunogenicity of engineered antibodies. Methods, 36, 3–10
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, et al. (2010). Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nature Biotechnol, 28, 1203–7
   PubMed Web of Science ®Google Scholar
• Isambert N, Freyer G, Zanetta S, et al. (2012). Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res, 18, 1743–50
   PubMed Web of Science ®Google Scholar
• Israel EJ, Wilsker DF, Hayes KC, et al. (1996). Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology, 89, 573–8
   PubMed Web of Science ®Google Scholar
• Iyer U, Kadambi VJ. (2011). Antibody drug conjugates – Trojan horses in the war on cancer. J Pharmacol Toxicol Methods, 64, 207–12
   PubMed Web of Science ®Google Scholar
• Jazayeri JA, Carroll GJ. (2008). Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs, 22, 11–26
   PubMed Web of Science ®Google Scholar
• Jiang XR, Song A, Bergelson S, et al. (2011). Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov, 10, 101–11
   PubMed Web of Science ®Google Scholar
• Junghans RP, Anderson CL. (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A, 93, 5512–6
   PubMed Web of Science ®Google Scholar
• Kacskovics I, Mayer B, Kis Z, et al. (2006). Cloning and characterization of the dromedary (Camelus dromedarius) neonatal Fc receptor (drFcRn). Dev Comp Immunol, 30, 1203–15
   PubMed Web of Science ®Google Scholar
• Kacskovics I, Wu Z, Simister NE, et al. (2000). Cloning and characterization of the bovine MHC class I-like Fc receptor. J Immunol, 164, 1889–97
   PubMed Web of Science ®Google Scholar
• Kandil E, Egashira M, Miyoshi O, et al. (1996). The human gene encoding the heavy chain of the major histocompatibility complex class I-like Fc receptor (FCGRT) maps to 19q13.3. Cytogenet Cell Genet, 73, 97–8
   PubMedGoogle Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. (2006). Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313, 670–3
   PubMed Web of Science ®Google Scholar
• Kemshead JT, Hopkins K. (1993). Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: a review. J R Soc Med, 86, 219–24
   PubMed Web of Science ®Google Scholar
• Kessel A, Ammuri H, Peri R, et al. (2007). Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol, 179, 5571–5
   PubMed Web of Science ®Google Scholar
• Keystone EC, Schiff MH, Kremer JM, et al. (2004). Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 50, 353–63
   PubMed Web of Science ®Google Scholar
• Kim J, Bronson CL, Hayton WL, et al. (2005). Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol, 290, G352–60
   Web of Science ®Google Scholar
• Kim J, Bronson CL, Wani MA, et al. (2008). Beta 2-microglobulin deficient mice catabolize IgG more rapidly than FcRn- alpha-chain deficient mice. Exp Biol Med, 233, 603–9
   PubMed Web of Science ®Google Scholar
• Kim J, Hayton WL, Robinson JM, Anderson CL. (2007). Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol, 122, 146–55
   PubMed Web of Science ®Google Scholar
• Kim JK, Firan M, Radu CG, et al. (1999). Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol, 29, 2819–25
   PubMed Web of Science ®Google Scholar
• Kim JK, Tsen MF, Ghetie V, Ward ES. (1994). Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol, 24, 2429–34
   Google Scholar
• Kobayashi K, Qiao SW, Yoshida M, et al. (2009). An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology, 137, 1746–56 e1
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495–7
   PubMed Web of Science ®Google Scholar
• Koren E, De Groot AS, Jawa V, et al. (2007). Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein. Clinical Immunol, 124, 26–32
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, et al. (2003). Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New Engl J Med, 349, 1907–15
   PubMed Web of Science ®Google Scholar
• Krueger GG, Papp KA, Stough DB, et al. (2002). A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol, 47, 821–33
   PubMed Web of Science ®Google Scholar
• Kuo TT, De Muinck EJ, Claypool SM, et al. (2009). N-glycan moieties in neonatal Fc receptor determine steady-state membrane distribution and directional transport of IgG. J Biol Chem, 284, 8292–300
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, et al. (2005). Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant, 5, 443–53
   PubMed Web of Science ®Google Scholar
• Leach JL, Sedmak DD, Osborne JM, et al. (1996). Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol, 157, 3317–22
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, et al. (2003). An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol, 139, 719–27
   PubMed Web of Science ®Google Scholar
• Lei TC, Scott DW. (2005). Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood, 105, 4865–70
   PubMed Web of Science ®Google Scholar
• Li Z, Palaniyandi S, Zeng R, et al. (2011). Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A, 108, 4388–93
   PubMed Web of Science ®Google Scholar
• Lonberg N. (2008). Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol, 20, 450–9
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, et al. (2000). Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. New Engl J Med, 342, 763–9
   PubMed Web of Science ®Google Scholar
• Low SC, Nunes SL, Bitonti AJ, Dumont JA. (2005). Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod, 20, 1805–13
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Gonzalez J, Bagel J, et al. (2003). Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol, 42, 224–30
   PubMed Web of Science ®Google Scholar
• Lu L, Palaniyandi S, Zeng R, et al. (2011). A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol, 85, 10542–53
   PubMed Web of Science ®Google Scholar
• Magdelaine-Beuzelin C, Vermeire S, Goodall M, et al. (2009). IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics, 19, 383–7
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell J, Ragni M, et al. (2013). Phase 3 clinical study of recombinant Fc fusion factor VIII (rFVIIIFc) demonstrated safety, efficacy and improved pharmacokinetics (A-LONG). Haemophilia, 19, 70
   Web of Science ®Google Scholar
• Martin WL, West Jr AP, Gan L, Bjorkman PJ. (2001). Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell, 7, 867–77
   PubMed Web of Science ®Google Scholar
• Mayer B, Zolnai A, Frenyo LV, et al. (2002a). Localization of the sheep FcRn in the mammary gland. Vet Immunol Immunopathol, 87, 327–30
   PubMed Web of Science ®Google Scholar
• Mayer B, Zolnai A, Frenyo LV, et al. (2002b). Redistribution of the sheep neonatal Fc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs. Immunology, 107, 288–96
   PubMed Web of Science ®Google Scholar
• Mayer L, Kaser A, Blumberg RS. (2012). Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology, 143, 13–7
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladstein G, et al. (2011). Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum, 63, 939–48
   PubMed Web of Science ®Google Scholar
• Medesan C, Matesoi D, Radu C, et al. (1997). Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol, 158, 2211–7
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, et al. (2010). The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 62, 3077–87
   PubMed Web of Science ®Google Scholar
• Molineux G, Newland A. (2010). Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol, 150, 9–20
   PubMed Web of Science ®Google Scholar
• Montoyo HP, Vaccaro C, Hafner M, et al. (2009). Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A, 106, 2788–93
   PubMed Web of Science ®Google Scholar
• Moreland L, Bate G, Kirkpatrick P. (2006). Abatacept. Nature Rev Drug Discov, 5, 185–6
   PubMed Web of Science ®Google Scholar
• Munafo A, Priestley A, Nestorov I, et al. (2007). Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol, 63, 647–56
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. (2010). Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov, 9, 767–74
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. (2007). The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med, 204, 11–15
   PubMed Web of Science ®Google Scholar
• Nplate. (2011). Prescribing information. Available from: http://pi.amgen.com/united_states/nplate/nplate_pi_hcp_english.pdf [last accessed 24 Apr 2012]
   Google Scholar
• Nulojix. (2011). Prescribing Information. Available from: http://packageinserts.bms.com/pi/pi_nulojix.pdf [last accessed 24 Apr 2012]
   Google Scholar
• Ober RJ, Martinez C, Lai X, et al. (2004a). Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A, 101, 11076–81
   PubMed Web of Science ®Google Scholar
• Ober RJ, Martinez C, Vaccaro C, et al. (2004b). Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol, 172, 2021–9
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. (2001). Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol, 13, 1551–9
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Woods RM, et al. (2009). Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol, 46, 1750–5
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Pavlova A. (2006). Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia, 12, 15–22
   PubMed Web of Science ®Google Scholar
• Orban T, Bundy B, Becker DJ, et al. (2011). Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet, 378, 412–9
   PubMed Web of Science ®Google Scholar
• Orencia. (2011). Prescribing Information. Available from: http://packageinserts.bms.com/pi/pi_orencia.pdf [last accessed 24 Apr 2012]
   Google Scholar
• Padler-Karavani V, Yu H, Cao H, et al. (2008). Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology, 18, 818–30
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15, 171–85
   PubMed Web of Science ®Google Scholar
• Patel DA, Puig-Canto A, Challa DK, et al. (2011). Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol, 187, 1015–22
   PubMed Web of Science ®Google Scholar
• Patel TP, Parekh RB, Moellering BJ, Prior CP. (1992). Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem J, 285, 839–45
   PubMed Web of Science ®Google Scholar
• Pena-Rossi C, Nasonov E, Stanislav M, et al. (2009). An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus, 18, 547–55
   PubMed Web of Science ®Google Scholar
• Peters RT, Low SC, Kamphaus GD, et al. (2010). Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood, 115, 2057–64
   PubMed Web of Science ®Google Scholar
• Peters Jr T. (1977). Serum albumin: recent progress in the understanding of its structure and biosynthesis. Clin Chem, 23, 5–12
   PubMed Web of Science ®Google Scholar
• Peters Jr T. (1985). Serum albumin. Adv Protein Chem, 37, 161–245
   PubMedGoogle Scholar
• Petkova SB, Akilesh S, Sproule TJ, et al. (2006). Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol, 18, 1759–69
   PubMed Web of Science ®Google Scholar
• Powell J, Ozelo M, Pasi J, et al. (2013). Safety, efficacy, and improved pharmacokinetics (PK) demonstrated in a phase 3 clinical trial of extended half life recombinant Fc fusion factor IX (B-LONG). Haemophilia, 19, 76
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. (2012). Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, 119, 3031–7
   PubMed Web of Science ®Google Scholar
• Qiao SW, Kobayashi K, Johansen FE, et al. (2008). Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A, 105, 9337–42
   PubMed Web of Science ®Google Scholar
• Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. (1995). Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry, 34, 14649–57
   PubMed Web of Science ®Google Scholar
• Reichert JM. (2008). Monoclonal antibodies as innovative therapeutics. Curr Pharmaceut Biotechnol, 9, 423–30
   PubMed Web of Science ®Google Scholar
• Reichert JM. (2010). Antibodies to watch in 2010. MAbs, 2, 84–100
   PubMed Web of Science ®Google Scholar
• Reichert JM. (2012). Which are the antibodies to watch in 2012? MAbs, 4, 1–3
   PubMed Web of Science ®Google Scholar
• Rilonacept_Smpc. (2009). Summary of product characteristics. Available from: http://www.regeneron.com/ArcalystPI-US-Summary-EMEA/emea-combined-_rilonaceptSmPCFeb2012.pdf [last accessed 18 Apr 2012]
   Google Scholar
• Roberts JL, Ortonne JP, Tan JK, et al. (2010). The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis. J Am Acad Dermatol, 62, 968–78
   PubMed Web of Science ®Google Scholar
• Rodewald R. (1973). Intestinal transport of antibodies in the newborn rat. J Cell Biol, 58, 189–211
   PubMed Web of Science ®Google Scholar
• Rodewald R. (1976). pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol, 71, 666–9
   PubMed Web of Science ®Google Scholar
• Rodewald R. (1980). Distribution of immunoglobulin G receptors in the small intestine of the young rat. J Cell Biol, 85, 18–32
   PubMed Web of Science ®Google Scholar
• Rodewald R, Kraehenbuhl JP. (1984). Receptor-mediated transport of IgG. J Cell Biol, 99, 159s–64s
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. (2007). FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol, 7, 715–25
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ, et al. (2003). The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol, 170, 3528–33
   PubMed Web of Science ®Google Scholar
• Sanchez LM, Penny DM, Bjorkman PJ. (1999). Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry, 38, 9471–6
   Google Scholar
• Sandborn WJ, Colombel JF, Sands BE, et al. (2012). Abatacept for Crohn’s disease and ulcerative colitis. Gastroenterology, 143, 62–69 e4
   PubMed Web of Science ®Google Scholar
• Schnulle PM, Hurley WL. (2003). Sequence and expression of the FcRn in the porcine mammary gland. Vet Immunol Immunopathol, 91, 227–31
   PubMed Web of Science ®Google Scholar
• Schuck P, Radu CG, Ward ES. (1999). Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1. Mol Immunol, 36, 1117–25
   Google Scholar
• Schultze HE, Heremans JF. (1966). Molecular biology of human proteins: with special reference to plasma proteins. Nature and metabolism of extracellular proteins. New York: Elsevier
   Google Scholar
• Scott DW, De Groot AS. (2010). Can we prevent immunogenicity of human protein drugs? Ann Rheum Dis, 69, i72–6
   Web of Science ®Google Scholar
• Senter PD. (2009). Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol, 13, 235–44
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Valentino LA, et al. (2012). Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood, 119, 666–72
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, et al. (2001). High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem, 276, 6591–604
   PubMed Web of Science ®Google Scholar
• Simister NE, Mostov KE. (1989). An Fc receptor structurally related to MHC class I antigens. Nature, 337, 184–7
   PubMed Web of Science ®Google Scholar
• Simister NE, Rees AR. (1985). Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol, 15, 733–8
   PubMed Web of Science ®Google Scholar
• Simister NE, Story CM, Chen HL, Hunt JS. (1996). An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol, 26, 1527–31
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Tiffany MR, Szoka FC. (2012). Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A, 109, 16095–100
   PubMed Web of Science ®Google Scholar
• Spiekermann GM, Finn PW, Ward ES, et al. (2002). Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med, 196, 303–10
   PubMed Web of Science ®Google Scholar
• Stahl N, Radin A, Mellis S. (2009). Rilonacept – CAPS and beyond. Ann New York Acad Sci, 1182, 124–34
   PubMed Web of Science ®Google Scholar
• Stohl W. (2012). Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep, 14, 303–9
   PubMed Web of Science ®Google Scholar
• Stohl W, Hilbert DM. (2012). The discovery and development of belimumab: the anti-BLyS-lupus connection. Nature Biotechnol, 30, 69–77
   PubMed Web of Science ®Google Scholar
• Story CM, Mikulska JE, Simister NE. (1994). A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med, 180, 2377–81
   PubMed Web of Science ®Google Scholar
• Strober BE, Menon K. (2007). Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther, 20, 270–6
   PubMed Web of Science ®Google Scholar
• Sutton BJ, Phillips DC. (1983). The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G. Biochem Soc Trans, 11, 130–2
   Web of Science ®Google Scholar
• Tak PP, Thurlings RM, Rossier C, et al. (2008). Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum, 58, 61–72
   PubMed Web of Science ®Google Scholar
• Tangri S, Licalsi C, Sidney J, Sette A. (2002). Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem, 9, 2191–9
   PubMed Web of Science ®Google Scholar
• Tangvoranuntakul P, Gagneux P, Diaz S, et al. (2003). Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A, 100, 12045–50
   PubMed Web of Science ®Google Scholar
• Tao MH, Morrison SL. (1989). Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol, 143, 2595–601
   PubMed Web of Science ®Google Scholar
• Tesar DB, Cheung EJ, Bjorkman PJ. (2008). The chicken yolk sac IgY receptor, a mammalian mannose receptor family member, transcytoses IgY across polarized epithelial cells. Mol Biol Cell, 19, 1587–93
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y, et al. (2007). Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol, 143, 719–26
   PubMed Web of Science ®Google Scholar
• Tzaban S, Massol RH, Yen E, et al. (2009). The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol, 185, 673–84
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Bawdon R, Wanjie S, et al. (2006). Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A, 103, 18709–14
   PubMed Web of Science ®Google Scholar
• Vallee S, Rakhe S, Reidy T, et al. (2012). Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway. J Interferon Cytokine Res, 32, 178–84
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Kinnman N, Vincent E, et al. (2011). Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum, 63, 1782–92
   PubMed Web of Science ®Google Scholar
• Vaughn DE, Bjorkman PJ. (1998). Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure, 6, 63–73
   PubMed Web of Science ®Google Scholar
• Vaughn DE, Milburn CM, Penny DM, et al. (1997). Identification of critical IgG binding epitopes on the neonatal Fc receptor. J Mol Biol, 274, 597–607
   Google Scholar
• Viglietta V, Bourcier K, Buckle GJ, et al. (2008). CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology, 71, 917–24
   PubMed Web of Science ®Google Scholar
• Vincenti F, Blancho G, Durrbach A, et al. (2010). Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol, 21, 1587–96
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Terry WD. (1990). Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Investig, 86, 2093–8
   PubMed Web of Science ®Google Scholar
• Walsh G. (2010). Post-translational modifications of protein biopharmaceuticals. Drug Discov Today, 15, 773–80
   PubMed Web of Science ®Google Scholar
• Walsh G, Jefferis R. (2006). Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol, 24, 1241–52
   PubMed Web of Science ®Google Scholar
• Wang TF, Lockhart AC. (2012). Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol, 6, 19–30
   PubMedGoogle Scholar
• Wang W, Lu P, Fang Y, et al. (2011). Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos, 39, 1469–77
   PubMed Web of Science ®Google Scholar
• Wani MA, Haynes LD, Kim J, et al. (2006). Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A, 103, 5084–9
   PubMed Web of Science ®Google Scholar
• Ward ES, Martinez C, Vaccaro C, et al. (2005). From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell, 16, 2028–38
   PubMedGoogle Scholar
• Ward ES, Ober RJ. (2009). Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol, 103, 77–115
   PubMed Web of Science ®Google Scholar
• Ward ES, Zhou J, Ghetie V, Ober RJ. (2003). Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol, 15, 187–95
   PubMed Web of Science ®Google Scholar
• Watson D. (1965). Albumin and “total globulin” fractions of blood. Adv Clin Chem, 8, 237–303
   PubMedGoogle Scholar
• Weiner LM, Surana R, Wang S. (2010). Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol, 10, 317–27
   PubMed Web of Science ®Google Scholar
• West Jr AP, Bjorkman PJ. (2000). Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry, 39, 9698–708
   PubMed Web of Science ®Google Scholar
• West Jr AP, Herr AB, Bjorkman PJ. (2004). The chicken yolk sac IgY receptor, a functional equivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2 receptor homolog. Immunity, 20, 601–10
   PubMed Web of Science ®Google Scholar
• Wu AM, Senter PD. (2005). Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol, 23, 1137–46
   PubMed Web of Science ®Google Scholar
• Ye L, Zeng R, Bai Y, et al. (2011). Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol, 29, 158–63
   PubMed Web of Science ®Google Scholar
• Yeung YA, Leabman MK, Marvin JS, et al. (2009). Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol, 182, 7663–71
   PubMed Web of Science ®Google Scholar
• Ying T, Chen W, Gong R, et al. (2012). Soluble monomeric IgG1 Fc. J Biol Chem, 287, 19399–408
   PubMedGoogle Scholar
• Yoshida M, Claypool SM, Wagner JS, et al. (2004). Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity, 20, 769–83
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kobayashi K, Kuo TT, et al. (2006). Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest, 116, 2142–51
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, et al. (2010). Enhanced antibody half-life improves in vivo activity. Nat Biotechnol, 28, 157–9
   PubMed Web of Science ®Google Scholar
• Zambidis ET, Scott DW. (1996). Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci U S A, 93, 5019–24
   PubMed Web of Science ®Google Scholar
• Zhao X, Lapalombella R, Joshi T, et al. (2007). Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood, 110, 2569–77
   PubMed Web of Science ®Google Scholar
• Zhou J, Johnson JE, Ghetie V, et al. (2003). Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol, 332, 901–13
   PubMed Web of Science ®Google Scholar
• Zhu A, Hurst R. (2002). Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation, 9, 376–81
   PubMed Web of Science ®Google Scholar